← Back to Search

Transfusion Support for Blood Cancers (BRUOG-407 Trial)

N/A

Waitlist Available

Led By Pamela C Egan, MD

Research Sponsored by Adam Olszewski

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, on average 2 years

Awards & highlights

BRUOG-407 Trial Summary

This trial is testing whether offering to pay for blood transfusions for hospice patients with blood cancer will encourage them to enroll earlier, improving their quality of life.

Who is the study for?

This trial is for adults with advanced blood cancers like leukemia or lymphoma who need regular blood transfusions and have chosen to stop cancer treatments. They must be eligible for hospice care as determined by their hematologist, but cannot join if they can't communicate in English or have a major psychiatric illness.Check my eligibility

What is being tested?

The study aims to see if covering the cost of blood transfusions for patients on hospice care encourages earlier enrollment and improves end-of-life care. It's testing whether removing financial barriers affects when patients with blood cancers choose to enter hospice.See study design

What are the potential side effects?

Since this trial involves standard transfusion support, side effects may include allergic reactions, fever, iron overload from multiple transfusions, infection risk from donated blood, and lung injury related to fluid overload.

BRUOG-407 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, on average 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, on average 2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, on average 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Proportion of eligible patients choosing to participate in the care model under study rather than standard of care.

Secondary outcome measures

Death in an acute care hospital

Number of days in the ICU in the last 30 days of life

Receipt of chemotherapy in the last 14 days of life

+1 more

BRUOG-407 Trial Design

1Treatment groups

Experimental Treatment

Group I: Intervention armExperimental Treatment1 Intervention

Patients with aggressive hematologic malignancies who are hospice eligible, not pursuing further cancer directed therapy, and whose primary hematologist is planning to initiate a conversation regarding transition to hospice will be eligible for enrollment.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Adam OlszewskiLead Sponsor

2 Previous Clinical Trials

63 Total Patients Enrolled

Pamela C Egan, MDPrincipal InvestigatorRhode Island Hospital

Media Library

Transfusion support Clinical Trial Eligibility Overview. Trial Name: NCT05063591 — N/A

Acute Myeloid Leukemia Research Study Groups: Intervention arm

Acute Myeloid Leukemia Clinical Trial 2023: Transfusion support Highlights & Side Effects. Trial Name: NCT05063591 — N/A

Transfusion support 2023 Treatment Timeline for Medical Study. Trial Name: NCT05063591 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are enrolled in the research project?

"That is correct. According to clinicaltrials.gov, this medical trial has been open since July 9th 2021 and is actively looking for 20 volunteers from one site. The details have recently been updated on November 4th 2021."

Answered by AI

Do you have any openings for volunteers in this experiment?

"Affirmative. The clinicaltrial.gov listing affirms that this investigation is still recruiting participants, which was originally posted on July 9th 2021 and updated most recently on the 4th of November 2021. Recruiting efforts are focused on acquiring 20 volunteers from a single site."

Answered by AI

What are the major aims of this research endeavor?

"The principal result of this two-year research project is the percentage of qualified patients who opt for the experimental treatment plan instead of standard care. Auxiliary results include whether or not a patient received chemotherapy in their last 14 days, if they passed away in an acute setting, and how long they were enrolled on hospice."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Removing Transfusion Dependence as a Barrier to Hospice Enrollment

Adam Olszewski 2021. "Removing Transfusion Dependence as a Barrier to Hospice Enrollment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05063591.